artificial pancreas technology


SDRI is on the cutting edge of research into new technologies designed to improve the lives of people living with diabetes. We have participated in key pivotal trials of commercial automated insulin delivery devices, and served as a clinical site in the trials of Tandem Diabetes’ Control-IQ and Basal-IQ technology, as well as for the hybrid closed loop system Omnipod 5. We have also performed studies with key partners around the country, including Harvard University, Mayo Clinic and the University of California Santa Barbara.

In 2020 SDRI had 3,164 subjects participate in clinical research for a hybrid closed loop system, or Artificial Pancreas. While huge milestones have been made at SDRI in Artificial Pancreas technology, there is still substantial work to be done.

Currently, SDRI is doing groundbreaking research, funded by the National Institutes of Health, studying automated insulin delivery in pregnant women with type 1 diabetes. Our goal is to address the needs of children, adolescents, adults, and seniors with diabetes to improve clinical outcomes.